Innoviva Cash Flow Statement
NASDAQ: INVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Innoviva free cash flow
In fiscal 2025, Innoviva generated $196.9 million of operating cash flow and spent $1.1 million on capital expenditures. That left free cash flow of $195.8 million, a free-cash-flow margin of 47.6% of revenue. Free cash flow was up 3.9% from the prior year's $188.4 million.
Innoviva returned $4.5 million to shareholders through share repurchases, equal to 2% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Innoviva cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 271.17M | 23.39M | 179.72M | 220.26M | 368.84M | 293.81M | 190.99M | 406.33M | 134.27M | 59.54M |
| Net Income growth (YoY) | +1059.22% | -86.98% | -18.41% | -40.28% | +25.53% | +53.83% | -53.00% | +202.62% | +125.53% | — |
| Depreciation & Amortization | — | — | — | — | 13.83M | 13.84M | 13.87M | 13.87M | 13.98M | 13.95M |
| Stock-Based Compensation | 9.45M | 6.37M | 5.84M | 7.35M | 2.02M | 1.70M | 2.06M | 3.23M | 9.83M | 8.30M |
| Change in Working Capital | -28.38M | -52.62M | -18.56M | 4.66M | -296.00K | 860.00K | -413.00K | -2.27M | -2.71M | -1.32M |
| Operating Cash Flow | 196.93M | 188.69M | 141.06M | 201.73M | 363.81M | 313.11M | 257.46M | 223.53M | 141.75M | 60.98M |
| Capital Expenditures | -1.13M | -270.00K | -411.00K | -67.00K | 0 | -13.00K | -12.00K | 0 | 0 | -278.00K |
| Investing Cash Flow | 40.50M | -63.79M | -66.76M | -56.63M | 43.72M | -314.94M | -18.00M | 3.52M | -23.24M | -4.58M |
| Dividends Paid | — | — | — | — | 0 | 0 | -11.00K | -80.00K | -281.00K | -960.00K |
| Share Repurchases | -4.53M | -14.78M | -75.73M | -8.50M | -394.15M | 0 | 0 | 0 | -97.50M | -78.09M |
| Debt Issued | — | 0 | 0 | 252.54M | 0 | 0 | — | — | — | 0 |
| Debt Repaid | — | 0 | -96.20M | -165.13M | 0 | 0 | — | — | — | — |
| Financing Cash Flow | 8.55M | -13.45M | -171.84M | -55.57M | -452.50M | -29.79M | -23.78M | -237.97M | -163.19M | -97.57M |
| Net Change in Cash | 245.98M | 111.45M | -97.54M | 89.52M | -44.96M | -31.61M | 215.68M | -10.92M | -44.68M | -41.16M |
| Free Cash Flow | 195.80M | 188.42M | 140.65M | 201.66M | 363.81M | 313.10M | 257.45M | 223.53M | 141.75M | 60.71M |
This table shows 10 annual periods of Innoviva's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow INVA's reporting calendar. What is a cash flow statement?